Dallas, TX (PRWEB) February 14, 2013
The prescription drug resource center DrugRisk.com is alerting patients taking the popular blood thinner Pradaxa of a new study added to the site which shows the anticoagulant may have a greater risk of causing fatal bleeding than alternatives.
“The goal of DrugRisk is to improve the patient drug experience by providing the latest drug warnings, recalls, studies and litigation news. Informed patients can better discuss side effect options with their doctor and decide if they need legal advice,“ explains DrugRisk representative Ryan Mayer.
The resource center has previously added information showing experts disagree about the risk of Pradaxa bleeding. The FDA recently issued an update that the drug carries the same risks as warfarin.* However, the American College of Cardiology has warned that Pradaxa use can significantly increase the risk of bleeding complications compared to warfarin.**
Now, new information added to DrugRisk from the Institute for Safe Medication Practices ranks anticoagulants like Pradaxa among the highest risk outpatient drugs. Also, in reviewing adverse event reports of hemorrhaging submitted to the FDA, the institute found bleeding from Pradaxa is almost 5 times as likely to result in death than with warfarin.***
DrugRisk has learned that, due to the number of patients filing Pradaxa lawsuits for bleeding side effects, the cases are being consolidated in a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf